Wells Fargo & Co. upgraded shares of C R Bard Inc (NYSE:BCR) from a market perform rating to an outperform rating in a research note issued to investors on Friday morning.

Several other brokerages also recently weighed in on BCR. Bank of America Corp. downgraded C R Bard from a buy rating to a neutral rating in a research report on Friday, July 8th. JPMorgan Chase & Co. increased their price target on C R Bard from $214.00 to $225.00 and gave the stock a neutral rating in a research report on Wednesday, July 27th. BMO Capital Markets reaffirmed a hold rating and set a $240.00 price target on shares of C R Bard in a research report on Wednesday, July 27th. Jefferies Group increased their price target on C R Bard from $215.00 to $237.00 and gave the stock a hold rating in a research report on Wednesday, July 27th. Finally, Citigroup Inc. increased their price target on C R Bard from $241.00 to $265.00 and gave the stock a buy rating in a research report on Wednesday, July 27th. Thirteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. C R Bard currently has an average rating of Hold and an average target price of $233.00.

Shares of C R Bard (NYSE:BCR) opened at 228.51 on Friday. C R Bard has a one year low of $172.21 and a one year high of $239.43. The company has a market capitalization of $16.78 billion, a PE ratio of 53.14 and a beta of 0.57. The stock has a 50 day moving average price of $220.37 and a 200 day moving average price of $217.69.

C R Bard (NYSE:BCR) last announced its quarterly earnings results on Tuesday, July 26th. The company reported $2.54 earnings per share for the quarter, topping the consensus estimate of $2.47 by $0.07. The company had revenue of $931.50 million for the quarter, compared to the consensus estimate of $915.22 million. C R Bard had a return on equity of 48.43% and a net margin of 9.20%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period last year, the firm earned $2.27 EPS. On average, equities research analysts predict that C R Bard will post $10.17 earnings per share for the current year.

In related news, VP Betty D. Larson sold 4,032 shares of the firm’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $225.33, for a total value of $908,530.56. Following the transaction, the vice president now directly owns 10,298 shares of the company’s stock, valued at approximately $2,320,448.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP John A. Deford sold 7,928 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $221.06, for a total transaction of $1,752,563.68. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its position in C R Bard by 415.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the company’s stock worth $104,000 after buying an additional 357 shares during the period. Whittier Trust Co. of Nevada Inc. raised its position in C R Bard by 43.7% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 454 shares of the company’s stock worth $107,000 after buying an additional 138 shares during the period. NN Investment Partners Holdings N.V. acquired a new position in C R Bard during the first quarter worth $100,000. Acrospire Investment Management LLC acquired a new position in C R Bard during the first quarter worth $101,000. Finally, LSV Asset Management acquired a new position in C R Bard during the second quarter worth $123,000. 87.90% of the stock is currently owned by institutional investors and hedge funds.

C R Bard Company Profile

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Receive News & Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.